Introduction
============

Nasopharyngeal carcinoma (NPC) is a prevalent form of cancer in men aged between 20 and 44 years in parts of Southeast Asia [@B1]. Furthermore, it is prevalent in southern China, especially Guangdong province [@B2], where it has even been termed "Canton tumor", and affects a significant proportion of the population in these geographically higher risk areas. The Canton-style diet is regarded as an important modifier of the NPC endemic and may partially account for the geographic distribution of NPC incidence [@B3]. Patients with undifferentiated NPC, which accounts for 90% of cases in endemic regions, are generally sensitive to radiation and chemotherapy [@B4]. Radiotherapy with or without chemotherapy is therefore the mainstream choice of treatment for primary NPC. Currently, modern anticancer strategies have provided opportunities to improve local control and survival in NPC [@B5]. Precision radiotherapy techniques have emerged including three-dimensional conformal radiotherapy (3DCRT), intensity-modulated radiation therapy (IMRT), and stereotactic radiosurgery (SRS). The regimens of neoadjuvant chemotherapy based mainly on cisplatin, in combination with paclitaxel, docetaxel, 5-fluorouracil, and gemcitabine have shown encouraging results in NPC [@B6]. Novel therapies targeting the epidermal growth factor receptor (EGFR) including nimotuzumab [@B7] and autologous cytotoxic T lymphocytes targeting EBV [@B8] have the potential to obtain optimal outcomes with minimal toxicity to the patient. Outcomes in patients with NPC have improved mainly because of these advances in comprehensive therapy strategies. However, although the currently established therapy for NPC has significantly improved, half of patients will experience local regional failure and distant metastasis during follow-up [@B9]. It has demonstrated that recurrent head and neck tumors might be intrinsically more radioresistant than the primary tumors. Radiation can induce tissue fibrosis and microvasculature damage, while altering the tumor microenvironment by stimulating hypoxia status, resulting in significant difficulties for treatment [@B10]. Treating recurrent NPC is always a huge challenging clinical problem, inducing limited local control. Further individualized management based on existing biomarkers should be analyzed more deeply.

In recent years, much attention has been given to the correlation between tumor development, progression and metastasis, and the coagulation and fibrinolysis system. Cancer-associated thrombosis significantly affects the lives of patients to their detriment. Indeed, research data suggests that targeting the coagulation system or fibrinolysis system might influence the course of malignant disease [@B11]. The D-dimer is known as a degradation product of fibrin, which is one of the signals that activates the fibrinolytic system, and appears in the blood as a small peptide fragment [@B12]. In most tumors, elevated D-dimer levels indicate a more advanced stage and increased risk for death [@B13]. They have been evidenced in progression and metastasis [@B14] in malignancies such as lung cancer [@B15], gastric cancer [@B16], ovarian cancer [@B17], esophageal cancer [@B18], and NPC [@B19]. Furthermore, it has been revealed that plasma D-dimer levels may be helpful in evaluating the response to chemotherapy in patients with metastatic colorectal cancer [@B20].

Therefore, in the present study, we aimed to explore the association of pretreatment plasma D-dimer levels with clinical and pathological factors as well as the treatment outcomes in patients with NPC. In addition, we attempted to combine the pretreatment albumin level to further assess the prognostic value of the both.

Materials and Methods
=====================

Patients
--------

Demographic and clinical data from 511 patients who underwent radiotherapy between January 2010 and October 2013 for NPC were evaluated in this retrospective study. We routinely collected the laboratory testing data before treatment (plasma D-dimer, Epstein-Barr virus (EBV), serum albumin, and platelet levels). The staging affairs included a complete medical history, physical examination, direct re-optic nasopharyngoscopy, nasopharyngeal and neck magnetic resonance imaging (MRI), abdominal ultrasound, chest radiography and entire body bone scans, with or without positron emission tomography-computed tomography (PET-CT). The patients were restaged using the 8th edition of the International Union against Cancer/American Joint Committee on Cancer (UICC/AJCC) [@B21].

This study was approved by the Research Ethics Committee of Sun Yat-sen University Cancer Center, Guangzhou, China. The inclusion criteria for this study were as follows: [@B1] newly pathologically diagnosed primary NPC, [@B2] no history of previous anticancer therapy and first received radiotherapy with or without chemotherapy in our hospital, and [@B3] adequate clinical information in the medical record. Patients were excluded from the study for the following reasons: [@B1] venous or arterial thromboembolism within the preceding 3 months, [@B2] continuous anticoagulation with vitamin K antagonists (VKAs) or low-molecular-weight heparins, [@B3] known congenital thrombophilia, ongoing anticoagulant treatment, pregnancy, stroke or neurosurgery within 6 months, and [@B4] had developed metastasis at diagnosis.

Treatment
---------

In our study, a standard multi-therapeutic protocol was used to treat the patients with NPC. All patients received intensity-modulated radiation therapy (IMRT), while radiation therapy alone was used for stage I patients, and radiation with concurrent platinum-based chemotherapy was used to treat stage II patients. Concurrent chemoradiotherapy, with or without neoadjuvant or adjuvant chemotherapy, was used for advanced stage NPC (stages III and IVA-B). Neoadjuvant or adjuvant chemotherapy consisted of cisplatin with 5-fluorouracil or cisplatin with taxane, administered every 3 weeks for 2 or 3 cycles. The concurrent chemotherapy regimen consisted of cisplatin administered on weeks 1, 4, and 7 of radiotherapy, or weekly. All patients at the study institution were treated according to the principle of treatment for NPC patients at Sun Yat-sen University Cancer Center, Guangzhou, China. It had been clarified in our previously published paper [@B22].

Measurement of D dimer levels
-----------------------------

In all patients, peripheral blood samples were collected within 1 week before treatment. The levels of D-dimer were measured using a nephelometry immunoassay (Axis-Shield PoC AS, Norway) at our hospital. We used a cutoff level of 0.675 µg/ml to distinguish between a high and low group according to the ROC curve analysis. Furthermore, other pretreatment laboratory data including EBV DNA and platelet levels were also collected from medical records in our study. The median albumin value was 45 g/L. Accordingly, the cutoff values of D dimer and albumin were defined as 0.675 µg/ml and 45 g/L, respectively. Patients were distributed into three groups: DA group 1 represented low D dimer levels (\< 0.675 µg/ml) and high albumin levels (≥ 45 g/L); high D dimer levels and high albumin levels, or low D dimer levels and low albumin levels were assigned DA group 2; DA group 3 was defined as that with high D dimer levels and low albumin levels.

Follow-up
---------

Follow-up evaluations were performed every 3 months within the first 3 years, 6 months in the following 3-5 years, and annually thereafter until death. The surveillance strategy following treatment included physical examination, nasopharyngoscopy, nasopharyngeal and neck MRI, chest CT, abdominal ultrasonography, bone marrow scan (if any symptoms of bone metastasis), EBV DNA copy load, and monitoring of other haematological measurements.

Follow-up was measured from date of first diagnosis to either the date of death or loss to follow-up. Our primary endpoint was overall survival (OS). Distant metastasis-free survival (DMFS) was included as a secondary endpoint in this study. OS was calculated from the date of the first NPC diagnosis to the date of death from any cause or patient censoring at the date of the last follow-up. DMFS was determined from the date of the first NPC diagnosis to the date of distant relapse or patient censoring at the date of the last follow-up.

Statistical analysis
--------------------

Receiver operating curve (ROC) analyses were used to determine the optimal cutoff values for the continuous plasma D-dimer, EBV DNA, and serum albumin levels. The Chi-square test was used to analyze the associations between pretreatment plasma D-dimer and clinicopathological features. The survival outcomes were analyzed using the Kaplan-Meier method, and comparisons were made using the log-rank test. Variables that reached a p-value of ≤ 0.05 in the univariate analysis were entered into multivariate analyses to examine their independent prognostic value on survival outcomes. The hazard ratios (HRs) with 95% confidence intervals (CI) were reported as relative risks for each independent factor. Statistical analysis was performed using the IBM SPSS statistical program package, version 22.0, IBM Corp. All statistical tests were two-sided; *P*\< 0.05 was defined as being statistically significant.

Results
=======

Correlations between Plasma Levels of D-Dimer and Other Clinical Characteristics
--------------------------------------------------------------------------------

A total of 511 patients with NPC who met our determined criteria were included in this study. Clinicopathologic characteristics and plasma D-dimer levels of the patients are summarized in Table [1](#T1){ref-type="table"}. In total, 338/511 (66.1%) patients had a pretreatment plasma D-dimer level below the cutoff value (0.675 ug/ml) and 173/511 (33.9%) were above the cutoff value. The median age of the 511 patients was 45 years. According to the analysis, the elevated D-dimer levels were significantly correlated with older age (*P* = 0.034), platelet levels (*P* = 0.043), and EBV DNA copy number (*P* = 0.035).

High pretreatment plasma D-dimer is an independent prognostic factor for poor OS
--------------------------------------------------------------------------------

The median follow-up duration period was 45.2 months (range, 2.1-79.8). For the entire cohort of 511 patients, the 3-year overall survival rate was 92.1%. In survival analysis, a high pretreatment plasma D-dimer level was associated with a poorer 3-year OS compared with a low pretreatment plasma D-dimer level (88.3% vs. 93.6%; Fig. [1](#F1){ref-type="fig"}A; log-rank test, *P* = 0.001) but DMFS was not significantly different (Fig.[1](#F1){ref-type="fig"}B; *P* = 0.381).

To determine the independent prognostic value of the plasma D-dimer level for OS and DMFS, multivariate analyses using a Cox proportional hazard model were performed to adjust for known prognostic parameters including smoking status, therapy regimen, overall stage, T category, N category, C-reactive protein, platelet levels, EBV DNA load, and D-dimer levels. The multivariate analyses demonstrated that a high pretreatment plasma D-dimer level was an independent prognostic factor for poor OS (HR 2.074, 95% CI 1.190-3.612, *P* = 0.010; Table [2](#T2){ref-type="table"}) after adjustment for other factors.

DA group is an independent prognostic factor for poor OS and DMFS
-----------------------------------------------------------------

In combination with albumin, the DA group also had prognostic value in NPC. In univariate analysis, the 3-year OS rate in DA group 1 vs. group 2 vs. group 3 was 93.9% vs. 92.0% vs. 85.9% (Fig. [2](#F2){ref-type="fig"}A; *P* = 0.002), respectively. After adjusting for smoking status, therapy regimen, overall stage, N category, C-reactive protein, and EBV DNA load, DA was shown to be an independent prognostic factor for OS (DA group 2 vs. group 1; HR 1.560, 95% CI 1.108-2.392, *P* = 0.041; DA group 3 vs. group 1; HR 1.930, 95% CI 1.145-3.251, *P* = 0.014; Table [3](#T3){ref-type="table"}). Meanwhile, the 3-year DMFS rate in DA group 1 vs. group 2 vs. group 3 was 94.2% vs. 91.2% vs. 86.6% (Fig. [2](#F2){ref-type="fig"}B; *P* = 0.003), respectively. After adjusting for overall stage, N category, C-reactive protein, and EBV DNA load, DA was found to be an independent prognostic factor for DMFS (DA group 2 vs. group 1; HR 2.194, 95% CI 1.127-4.272, *P* = 0.021; DA group 3 vs. group 1; HR 2.141, 95% CI 1.003-4.573, *P* = 0.049; Table [3](#T3){ref-type="table"}).

Discussion
==========

The presented data demonstrate that the pretreatment D-dimer levels were significantly associated with OS. However, they had no independently prognostic value for DMFS. When combined with albumin levels, the DA group could act as an independent prognostic marker for OS and DMFS in patients with NPC. We believe this is a promising new biomarker.

Currently, much research has focused on the relationship between the activation of the hemostatic system and tumors, which includes the platelet/coagulation/fibrinolysis systems [@B11], [@B23], [@B24]. Key steps in tumor progression, including cellular transformation, proliferation, tumor cell survival, and blood vessel formation (angiogenesis) can be mediated by components of these systems [@B25]. These mechanisms have also been attributed to the stimulation of tumor adhesion [@B26], growth [@B27], and metastasis [@B28]. The tumor microenvironment, which is influenced by hemostatic elements such as platelets, coagulation factors, fibrinogen and D-dimers are known as key factors in the multiple stages of cancer progression. Indeed, plenty of studies have been conducted to confirm the mechanism and associations with cancer.

Epithelial-mesenchymal transition (EMT), an important process during the onset of cancer cell migration, invasion, and metastatic dissemination, is also a core event in both tumorigenesis and developmental processes [@B29]. Protease activated receptor-1 (PAR1), known as the coagulation factor II (thrombin) receptor [@B30], is activated by thrombin and then consequently affects epithelial to myofibroblast transition. A study [@B31] revealed that these effects were clearly prevented by a specific PAR-1 antagonist, indicating the interaction with thrombin and EMT. As such, PAR-1 targeting therapy may interfere with EMT. Other studies reported that thrombin increases invasive activity through the thrombin receptor and that inhibition of PAR-1 expression reduces the invasive potential of tumors [@B32]. Additionally, vascular endothelial growth factor (VEGF), one of the critical factors in angiogenesis that contributes to metastasis, is upregulated by thrombin via PAR-1 in breast cancer cells [@B33]. Thrombin may be involved in bone metastasis mediated by VEGF secretion and studies have demonstrated that inhibition of thrombin is of great value in suppression of tumor metastasis [@B34].

The fibrinolytic system has attracted attention as a possible mediator of cancer progression in recent years. It is generally accepted that plasma D-dimer is a stable fibrin degradation product. Plasma D-dimer has been studied for the evaluation of its prognostic value in various cancers, including NPC, and the findings were similar to our analysis, while our study had focused on the combination of both D-dimer and albumin. Also, all the NPC patients we recruited received intensity-modulated radiation therapy (IMRT), and there have no studied about this. Thus, this may be of some aspects of novelty. We found that D-dimer levels were significantly associated with OS but not DMFS. Innovatively, in our study, a new marker called DA, which combined D-dimer with albumin, was identified as an independent factor of OS and DMFS in patients with NPC. DA was also strongly associated with postoperative survival in esophageal squamous cell carcinoma patients [@B35]. Therefore, DA may be a better and more precise indicator for the prognosis of patients with other cancers.

Though the present article provides a comprehensive overview of the mechanism of thrombin in cancer progression, and highlights the survival benefits that are indicated according to the stratification of hemostatic factors, other therapeutic approaches to cancer therapy have been developed by targeting platelets, coagulation, and fibrinolysis. In terms of hemostatic elements, this form of therapy is rarely in use. Although the currently established therapy for NPC includes effective IMRT and chemotherapy, given the high metastasis and recurrence rate, it is very important to identify prognostic factors for NPC that can help clinical decision-making. According to the results of our study, there is a hypothesis that reducing the D-dimer levels and improving the nutritious conditions may contribute to further survival benefit in NPC patients.

Study limitations
-----------------

There were some limitations to our study. Firstly, our study was a retrospective study with asmall sample size. Secondly, the value of plasma D-dimer was measured only once before treatment. Therefore, the surveillance of dynamic changes associated with D-dimer is needed to demonstrate and confirm the aforementioned relationships. Additionally, a ROC curve was commonly plotted to determine the cutoff value of plasma D-dimer for prognosis prediction. However, some studies selected the cutoff value according to the marginal value of the D-dimer. Thus, further sensitivity analysis is necessary to consider the various cutoff values. The third limitation was the short median follow-up time, and additional patient data will be reported after a longer follow-up duration. Furthermore, we cannot exclude that the patients with asymptomatic hematologic events could have influenced the accuracy of the D-dimer or impaired the disease course and patient survival.

Conclusions
===========

In summary, based on the results of the current study, we conclude that plasma D-dimer and the combination of D-dimer and albumin (DA) were independent prognostic biomarkers in patients with NPC. Although we were not able to precisely determine the definite mechanism underlying the prognostic value of D-dimer in this study, it is rational to suggest that patients with NPC with pretreatment increased D-dimer levels may need closer surveillance, and may even require adjuvant anti-fibrinolysis therapy.
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###### 

Association between D-dimer levels and clinicopathological features in patients with nasopharyngeal carcinoma (n = 511)

  Characteristic                  Total        D-dimer (µg/ml)   *P*-value^\*^   
  ------------------------------- ------------ ----------------- --------------- -------
                                  511 (100)    338 (66.1)        173 (33.9)      
  Age (years)                                                                    0.034
  \< 45                           256 (50.1)   180 (53.3)        76 (43.9)       
  ≥ 45                            255 (49.9)   158 (46.7)        97 (56.1)       
  Smoking                                                                        0.818
  Yes                             151 (29.5)   101 (29.9)        50 (28.9)       
  No                              360 (70.5)   237 (70.1)        123 (71.1)      
  Overall stage (8^th^ edition)                                                  0.663
  I+II                            154 (30.1)   104 (30.8)        50 (28.9)       
  III+IV                          357 (69.9)   234 (69.2)        123 (71.1)      
  T category                                                                     0.403
  T1-2                            193(37.8)    132 (39.1)        61 (35.3)       
  T3-4                            318 (62.2)   206 (60.9)        112 (64.7)      
  N category                                                                     0.666
  N0-1                            381 (74.6)   250 (74.0)        131 (75.7)      
  N2-3                            130 (25.4)   88 (26.0)         42 (24.3)       
  Treatment                                                                      0.373
  IMRT                            109 (21.3)   76 (22.5)         33 (19.1)       
  CT + IMRT                       402 (78.7)   262 (77.5)        140 (80.9)      
  Platelet (\^10^9^/L)                                                           0.043
  \< 249                          329 (64.4)   228 (67.5)        101 (58.4)      
  ≥ 249                           182 (35.6)   110 (32.5)        72 (41.6)       
  C-reactive protein(mg/L)                                                       0.148
  \< 3.86                         352 (68.9)   240 (71.0)        112 (64.7)      
  ≥ 3.86                          159 (31.1)   98 (29.0)         61 (35.63)      
  Albumin (g/L)                                                                  0.932
  \< 45                           297 (58.1)   196 (58.0)        101 (58.4)      
  ≥ 45                            214 (41.9)   142 (42.0)        72 (41.6)       
  EBV DNA (copies/ml)                                                            0.035
  \< 3775                         246 (48.1)   174 (51.5)        72 (41.6)       
  ≥ 3775                          265 (51.9)   164 (48.5)        101 (58.4)      
  Outcomes                                                                       
  Death                           55           24                31              
  Distant metastasis              67           44                23              
  Localregional relapse           17           14                3               

**Abbreviations:** IMRT = intensity-modulated radiation therapy; CT = chemotherapy.

\*Chi-square test

###### 

Cox\'s proportional hazards regression model of overall survival for the 511 patients with nasopharyngeal carcinoma

  Variable                        Univariate analysis    Multivariate analysis                         
  ------------------------------- ---------------------- ----------------------- --------------------- ----------
  Smoking                                                                                              
  Yes vs. no                      1.928 (1.132-3.286)    0.016                   2.191 (1.264-3.796)   0.005
  Therapy                                                                                              
  IMRT+CT vs. IMRT                2.299 (1.326-3.985)    0.003                   3.047 (1.710-5.429)   \< 0.001
  Overall stage (8^th^ edition)                                                                        
  III+IV vs. I+II                 9.117 (2.844-29.227)   \< 0.001                                      
  T category                                                                                           
  T3-4 vs. T1-2                   4.737 (2.140-10.487)   \< 0.001                                      
  N category                                                                                           
  N2-3 vs. N0-1                   3.318 (1.940-5.677)    \< 0.001                2.838 (1.556-5.177)   0.001
  C-reactive protein (mg/L)                                                                            
  ≥ 3.86 vs. \< 3.86              2.261 (1.331-3.841)    0.003                                         
  Platelet (\^10^9^/L)                                                                                 
  ≥ 249 vs. \< 249                1.992 (1.173-3.383)    0.011                                         
  EBV DNA (copies/ml)                                                                                  
  ≥ 3775 vs. \< 3775              3.177 (1.809-5.581)    \< 0.001                3.621 (2.010-6.523)   \< 0.001
  D-dimer (ug/ml)                                                                                      
  ≥ 0.675 vs. \< 0.675            2.423 (1.417-4.142)    0.001                   2.074 (1.190-3.612)   0.010

**Abbreviations:** HR = hazard ratio;CI = confidence interval

###### 

Multivariate analysis of overall survival and distant metastasis-free survival for the 511 patients with nasopharyngeal carcinoma

  Variable                        OS                    DMFS                             
  ------------------------------- --------------------- ---------- --------------------- -------
  Smoking                                                                                
  Yes vs. no                      2.205 (1.276-3.810)   0.005                            
  Therapy                                                                                
  IMRT+CT vs. IMRT                2.924 (1.644-5.199)   \< 0.001                         
  Overall stage (8^th^ edition)                                                          
  III+IV vs. I+II                                                  3.145(1.102-8.973)    0.032
  N category                                                                             
  N2-3 vs. N0-1                   2.690 (1.474-4.909)   0.001      1.989 (1.178-3.358)   0.010
  C-reactive protein (mg/L)                                                              
  ≥ 3.86 vs. \< 3.86                                               1.987 (1.239-3.187)   0.004
  EBV DNA (copies/ml)                                                                    
  ≥ 3775 vs. \< 3775              3.699 (2.056-6.658)   \< 0.001   1.660 (1.054-2.616)   0.029
  DA                                                                                     
  DA group1                       1                     0.038      1                     0.031
  DA group 2 vs. DA group1        1.560 (1.108-2.392)   0.041      2.194 (1.127-4.272)   0.021
  DA group 3 vs. DA group 1       1.930 (1.145-3.251)   0.014      2.141 (1.003-4.573)   0.049
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